Systematic (IUPAC) name | |
---|---|
(6R,7R)-7-{[2-(2-amino-1,3-thiazol-4-yl)-2-(carboxy methoxyimino)acetyl]amino}-3-ethenyl-8-oxo-5-thia- 1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | |
Identifiers | |
CAS number | 79350-37-1 |
ATC code | J01DD08 |
PubChem | CID 5362065 |
DrugBank | APRD00583 |
ChemSpider | 4514923 |
UNII | 97I1C92E55 |
KEGG | D00258 |
ChEMBL | CHEMBL1541 |
Chemical data | |
Formula | C16H15N5O7S2 |
Mol. mass | 453.452 g/mol |
SMILES | eMolecules & PubChem |
Pharmacokinetic data | |
Bioavailability | 40% to 50% |
Protein binding | Approximately 60% |
Half-life | Variable Average 3 to 4 hours |
Excretion | Renal and biliary |
Therapeutic considerations | |
Pregnancy cat. | B |
Legal status | ? |
Routes | Oral |
(what is this?) (verify) |
The usual dose is 400 mg in two divided doses for up to 5-7 days.
It was sold under the trade name Suprax in the USA, until 2003 when it was taken off the market by drug manufacturer Wyeth after its patent expired. The oral suspension form of "Suprax" was re-launched by Lupin in the USA.
No comments:
Post a Comment